Significance
PRRX2 mediates enzalutamide resistance via activation of the E2F and BCL2 pathways, which can be targeted with CDK4/6 and BCL2 inhibitors to reverse resistance.
Trial registration
ClinicalTrials.gov NCT02452008 NCT03751436 NCT03900884.
